Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy
In adults with type 2 diabetes who had not previously received insulin, once-weekly efsitora, administered in a fixed-dose regimen, was noninferior to once-daily glargine in reducing glycated hemoglobin levels. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT05662332.).
Authors
- Julio Rosenstock (ORCID: https://orcid.org/0000-0001-8324-3275)
- Alexander J. Knights (ORCID: https://orcid.org/0000-0001-8402-2212)
- Timothy S. Bailey (ORCID: https://orcid.org/0000-0003-4178-3462)
- Eden M Miller (ORCID: https://orcid.org/0000-0001-8733-8802)
- Jennifer Leohr (ORCID: https://orcid.org/0000-0001-5434-7905)
- Christopher J. Child (ORCID: https://orcid.org/0000-0002-6195-2780)
- Cyrus Desouza (ORCID: https://orcid.org/0000-0001-6660-0568)
- Lisa Connery
- Molly C. Carr
- Qianqian Wang (ORCID: https://orcid.org/0009-0005-9308-0584)
Institutions
- University of Nebraska at Omaha (US)
- Eli Lilly (United States) (US)
- Headlands Center for the Arts (US)
- Omaha VA Medical Center (US)
- AMCR Institute (US)
- Alliance for Multispecialty Research (United States) (US)
- Velocity Clinical Research (United States) (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-06-22
- DOI
- https://doi.org/10.1056/nejmoa2502796
- Citations
- 15
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 19.42
Funders
- Eli Lilly and Company